NovoCure
NVCR
242 hedge funds and large institutions have $1.68B invested in NovoCure in 2025 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 86 increasing their positions, 70 reducing their positions, and 29 closing their positions.
500% more call options, than puts
Call options by funds: $21.2M | Put options by funds: $3.53M
59% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 29
23% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 70
7% more funds holding
Funds holding: 227 → 242 (+15)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1% less capital invested
Capital invested by funds: $1.7B → $1.68B (-$14.8M)
1.86% less ownership
Funds ownership: 86.6% → 84.73% (-1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$24.1M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$20.3M |
| 3 |
BlackRock
New York
|
+$18.9M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$16.7M |
| 5 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$159M |
| 2 |
Coatue Management
New York
|
-$10.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.7M |
| 4 |
UBS AM
Chicago,
Illinois
|
-$7.16M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$6.85M |
NVCR Hedge Fund Activity: Q2 2025 in Review
242 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in NovoCure (NVCR) for Q2 2025, worth a combined $1.68B — down 0.87% from $1.7B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new NVCR positions and 29 closed out — a net gain of 17 holders — while 86 added to existing stakes and 70 trimmed.
The largest buyer was Soleus Capital Management, adding an estimated $24.1M. The largest seller was Capital International Investors, exiting entirely with an estimated $159M sold.
- 242 institutional investors held NovoCure (NVCR) as of Q2 2025, up from 227 in Q1 2025.
- Funds reported $1.68B of NovoCure stock for Q2 2025, down 0.87% quarter-over-quarter.
- 46 funds opened new NovoCure positions in Q2 2025 and 29 closed out, a net change of +17 holders.
- The largest NovoCure buyer in Q2 2025 was Soleus Capital Management, an estimated $24.1M added.
- The largest NovoCure seller in Q2 2025 was Capital International Investors, an estimated $159M sold.
Based on aggregated 13F filings for Q2 2025.